Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of breviscapine in hepatic stellate cell migration inhibition drug preparation

A technology of hepatic stellate cells and breviscapine, applied in the field of medicine, can solve the problems of hepatic stellate cell migration that have not been reported.

Inactive Publication Date: 2013-03-27
SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no relevant report on the role of breviscapine in inhibiting the migration of hepatic stellate cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of breviscapine in hepatic stellate cell migration inhibition drug preparation
  • Application of breviscapine in hepatic stellate cell migration inhibition drug preparation
  • Application of breviscapine in hepatic stellate cell migration inhibition drug preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] The scutellarin of the present invention is made into tablets according to methods known to those skilled in the art. Breviscapine tablets, each containing 20mg breviscapine, 15mg microcrystalline cellulose, 15mg micronized silica gel, 0.5mg magnesium stearate, and 8mg lactose. Usage: 2 tablets each time, 2-3 times a day, 5-6 days a week, every 3-4 weeks as a course of treatment.

Embodiment 2

[0067] The scutellarin of the present invention is made into capsules according to methods known to those skilled in the art. Breviscapine capsules, each capsule contains 20mg of breviscapine. Usage: 2 capsules each time, 2-3 times a day, 5-6 days a week, every 3-4 weeks as a course of treatment.

Embodiment 3

[0069] The scutellarin of the present invention is prepared into granules according to methods known to those skilled in the art. Breviscapine granules, each bag contains 20mg breviscapine, 15mg microcrystalline cellulose, 15mg micronized silica gel, 0.5mg stearic acid, and 8mg lactose. Usage: 2 bags each time, 2-3 times a day, 5-6 days a week, every 3-4 weeks as a course of treatment.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of breviscapine in hepatic stellate cell migration inhibition drug preparation. According to the present invention, a PDGF-induced human hepatic stellate cell line (LX-2) migration screening platform is designed, and results show that PDGF-induced hepatic stellate cell (HSC) migration can be inhibited with 10<-4>-10<-7> mol / L breviscapine.

Description

technical field [0001] The invention belongs to the field of traditional Chinese medicines, and in particular relates to the application of breviscapine in the preparation of medicines for inhibiting the migration of hepatic stellate cells. Background technique [0002] Breviscapine is a class of flavonoids isolated from Erigeron breviscapus. Its structural formula is identified as 4,5,6-trihydroxyflavone-7 glucuronide. It has a wide range of pharmacological effects and clinical applications. Studies have found that it has Improve heart and cerebrovascular blood flow, anti-platelet aggregation, anti-oxygen free radicals, enhance liver detoxification function, protect diabetic liver and kidney, etc. Ji Mingzhu et al. randomly divided patients with liver cirrhosis into two groups. The results showed that Erigeron breviscapus had anti-damage and anti-fibrosis effects on liver cirrhosis. The liver function of the treatment group was significantly improved (P<0.05), and the fi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P1/16
Inventor 徐列明张展
Owner SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com